Ardent Health, Inc. ($ARDT) reported second-quarter 2026 revenue of $1.6 billion, essentially in line with analyst expectations and down slightly from a year earlier.
Profitability came under pressure during the period. Gross profit fell to $338.6 million, operating profit declined to $55.8 million, and net income attributable to common shareholders dropped to $16.9 million. Diluted earnings per share came in at $0.12, below the estimate of $0.18.
The company did post stronger cash generation. Cash from operating activities rose to $196.7 million, while cash and cash equivalents increased to $724.5 million.
- Revenue: $1.6 billion
- Gross profit: $338.6 million
- Operating profit: $55.8 million
- Net income: $16.9 million
- Operating cash flow: $196.7 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Ardent Health, Inc. Insider Trading Activity
Ardent Health, Inc. insiders have traded $ARDT stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ARDT stock by insiders over the last 6 months:
- ROBERT DEMICHIEI purchased 11,260 shares for an estimated $98,299
- ALFRED LUMSDAINE (Chief Financial Officer) purchased 10,000 shares for an estimated $88,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Ardent Health, Inc. Hedge Fund Activity
We have seen 68 institutional investors add shares of Ardent Health, Inc. stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 657,903 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,631,649
- WOODLINE PARTNERS LP removed 641,232 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,488,945
- MILLENNIUM MANAGEMENT LLC removed 561,090 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $4,802,930
- MORGAN STANLEY removed 435,338 shares (-59.9%) from their portfolio in Q1 2026, for an estimated $3,726,493
- AQR CAPITAL MANAGEMENT LLC added 368,414 shares (+64.2%) to their portfolio in Q1 2026, for an estimated $3,153,623
- UBS GROUP AG added 334,003 shares (+286.3%) to their portfolio in Q1 2026, for an estimated $2,859,065
- PEREGRINE CAPITAL MANAGEMENT LLC removed 297,394 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,545,692
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Ardent Health, Inc. Price Targets
Multiple analysts have issued price targets for $ARDT recently. We have seen 3 analysts offer price targets for $ARDT in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Ben Hendrix from RBC Capital set a target price of $12.0 on 07/09/2026
- A.J. Rice from UBS set a target price of $13.5 on 05/07/2026
- Whit Mayo from Leerink Partners set a target price of $15.0 on 03/06/2026
